Main Page
Faculty Deanship
Dean
Health Empowerment Unit
Strategic Planning Unit
Development and Quality Unit
Medical and Bioethics Unit
Vice Dean for Graduate Studies and Research
Vice Dean for Female Section
Vice dean for Academic Affairs
Examination and Assessment Unit
Internship and Alumni Unit
Student Research Unit
E-learning Unit
Student Mentoring and Support Unit
Community Service Unit
Talent and Creativity Care Unit
Continuing Education Unit
Neuroscience Research Unit
Vice Deanship of Clinical Affairs / Administration
Organizational Structure
Departments
Basic Sciences
Department of Anatomy
Department of Pharmacology
Department of Pathology
Department of Microbiology and Medical Parasitolog
Deparment of Clinical Biochemistry
Department of Physiology
Department of Medical Genetics
Clinical Sciences
Department of Otorhinolaryngology
Department of Obstetrics and Gynecology
Department of Hematology
Department of Medical Education
Department of Anesthesia
Department of Family Medicine
Department of Community Medicine
Department of Surgery
Department of Orthopedic Surgery
Department of ophthalmology
Department of Radiology
Department of Internal Medicine
Department of Pediatrics
Department of Emergency Medicine
Department of Urology
Department of Dermatology
Latest News
عربي
English
About
Admission
Academic
Research and Innovations
University Life
E-Services
Search
Faculty of Medicine
Document Details
Document Type
:
Article In Journal
Document Title
:
Topiramate For The Treatment of Infants with Early Myoclonic Encephalopathy.
علاج التوبيريميت لعلاج الصرع الطفولى
Document Language
:
English
Abstract
:
Background: Early myoclonic encephalopathy (EME) is a rare epileptic syndrome characterized by neonatal onset of severe recurrent seizures of multiple types often resistant to antiepileptic drugs (AEDs). Topiramate (TPM) is a new AED, which has a wide spectrum of antiepileptic activities suggesting a potentially valuable therapeutic profile. There are limited clinical data available on TPM use in infants. Methods: Prospective, open label, add on trial of TPM in treating a series of infants with EME. TPM was started at 12.5 mg/day and was increased by doubling the dose every week until the minimum effective dose was reached (seizure free outcome) or up to a maximum of 10 mg/kg/day. Results: Four consecutive infants (2 males and 2 females) were included. In addition to daily seizures, they all had global hypotonia, developmental delay, and progressive microcephaly. The syndrome was cryptogenic in 3, and one had nonketotic hyperglycinemia. Initial EEGs showed generalized epileptic burst suppression pattern. Infants were tried on multiple AEDs (6-11, mean 7.5) with no success. TPM was added at age 5-12 months (mean 9) reaching a maximum dose of 5.5-10 mg/kg/day (mean 7.6). The infants were then followed for up to 19 months (mean 13.5). After introducing TPM, one infant became completely seizure free and 3 had significant (>50%) seizure reduction. EEGs in 3 infants showed marked improvement. One infant had weight loss that resulted in discontinuing the drug after 6 months. Follow-up renal ultrasound was normal in all infants. Conclusions: TPM is effective and safe in treating infants with intractable epilepsy secondary to EME.
ISSN
:
0749-8063
Journal Name
:
Neurosciences Journal
Volume
:
2
Issue Number
:
8
Publishing Year
:
2003 AH
2003 AD
Article Type
:
Article
Added Date
:
Saturday, March 13, 2010
Researchers
Researcher Name (Arabic)
Researcher Name (English)
Researcher Type
Dr Grade
Email
محمد جان
jan, Mohammed
Researcher
Doctorate
Files
File Name
Type
Description
25918.doc
doc
Back To Researches Page